Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Trailhead Biosystems Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 3 distinct examiners across 2 distinct art units. This indicates that while the examiners are unique for each case, there is some overlap in the art units, with some of the pending matters likely residing within the same specialized group at the patent office.
The busiest examiner for the portfolio is STAVROU, CONSTANTINA E, who is responsible for 1 pending office action. Given that there are 3 pending office actions in total, the workload is split among the various examiners. This means that no single examiner dominates the prosecution landscape for the company, requiring the legal team to engage with various individuals to resolve the current workload.
The concentration of active cases within only 2 distinct art units suggests a thematic focus in the company's biotechnology filings. Practitioners can leverage their experience within these 2 distinct art units to inform their responses to the various examiners. Monitoring the specific tendencies of STAVROU, CONSTANTINA E will be important for the 1 pending action under their care, but a comprehensive strategy must account for all active examiners to ensure the portfolio advances effectively.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STAVROU, CONSTANTINA E | 1 | 43.7% | +36.9% |
| TAKENAKA, RISA | 1 | 27.3% | +100.0% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 22.2% | +35.7% |
| TRAN, KHOA NHAT | 1 | 43.2% | +53.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18071388 | METHODS AND COMPOSITIONS FOR MAINTAINING AND EXPANDING HEMATOPOIETIC STEM CELLS | TAKENAKA, RISA | 31d overdue |
| 17896781 | Methods and Compositions for Generating Human Forebrain Neural Progenitor Cells and for Maturation Thereof to Parvalbumin+ Interneurons | SPENCER, ANDREA LYNNE MORRIS | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18071388 | METHODS AND COMPOSITIONS FOR MAINTAINING AND EXPANDING HEMATOPOIETIC STEM CELLS | TAKENAKA, RISA | 31d overdue |
| 17748323 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN NEURAL PROGENITOR CELLS | TRAN, KHOA NHAT | 10d overdue |
| 17896781 | Methods and Compositions for Generating Human Forebrain Neural Progenitor Cells and for Maturation Thereof to Parvalbumin+ Interneurons | SPENCER, ANDREA LYNNE MORRIS | 14d |
| 18199415 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | STAVROU, CONSTANTINA E | — |
| Art Unit | Apps |
|---|---|
| 1632 | 3 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18199415 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | STAVROU, CONSTANTINA E | 1632 | §112 | Final Rejection | — | Pending | May 19, 2023 |
| 18071388 | METHODS AND COMPOSITIONS FOR MAINTAINING AND EXPANDING HEMATOPOIETIC STEM CELLS | TAKENAKA, RISA | 1632 | §103 | Final Rejection | 31d overdue | Pending | Nov 29, 2022 |
| 17896781 | Methods and Compositions for Generating Human Forebrain Neural Progenitor Cells and for Maturation Thereof to Parvalbumin+ Interneurons | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Final Rejection | 14d | Pending | Aug 26, 2022 |
| 17748323 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN NEURAL PROGENITOR CELLS | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | 10d overdue | Pending | May 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial